Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.30
-0.4800-3.25%
Post-market: 14.350.0500+0.35%19:30 EDT
Volume:969.16K
Turnover:14.04M
Market Cap:1.22B
PE:-8.19
High:15.00
Open:14.80
Low:14.17
Close:14.78
52wk High:25.77
52wk Low:4.52
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.07
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.50
PE(LYR):-30.75

Loading ...

Top Executive’s Surprise Move Shakes Up Monte Rosa Therapeutics Insider Activity

TIPRANKS
·
Apr 16

Monte Rosa CEO Markus Warmuth disposes 8,000 shares for $141,120

Reuters
·
Apr 16

Top Monte Rosa Therapeutics Executive Makes Notable Insider Stock Move

TIPRANKS
·
Apr 11

Monte Rosa Chief Business & Legal Officer Philip Nickson sells 5,845 shares for $103,410

Reuters
·
Apr 11

Monte Rosa Therapeutics Inc : Jefferies Assumes Coverage With Buy Rating; Target Price $30 VS $31

THOMSON REUTERS
·
Mar 30

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement

Simply Wall St.
·
Mar 28

A Look At Monte Rosa Therapeutics (GLUE) Valuation After Its Recent Share Price Pullback

Simply Wall St.
·
Mar 21

J.P. Morgan Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Mar 19

Monte Rosa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 18

Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Mar 18

Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Mar 18

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Mar 17

Monte Rosa Therapeutics Inc. publishes corporate presentation on molecular glue degrader pipeline with three clinical programs

Reuters
·
Mar 17

Monte Rosa Q4 net loss widens 244% to USD 46.14 million on revenue down 95% to USD 2.78 million

Reuters
·
Mar 17

BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million

Reuters
·
Mar 17

Monte Rosa Therapeutics Q4 Net Income USD -46.135 Million

THOMSON REUTERS
·
Mar 17

Monte Rosa Therapeutics Q4 Operating Expenses USD 52.496 Million

THOMSON REUTERS
·
Mar 17

Press Release: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Dow Jones
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16